Ann: Echo IQ Announces Positive Results From US Clinical Study, page-16

Thanks Dude.

Despite my ongoing concerns about governance and reporting aspects of how Echo IQ is run I will admit that this latest announcement is a good one and that it adds to what is already a quite compelling proposition. The way I read the last update of the timeline - which is from back in April!!! - they are hoping to lodge their 510(k) submission with the FDA in February / March next year. Not sure how long it will take for the FDA to process that submission. Anyway Profs Playford and Strange seem to be getting EchoIQ exposed to some serious actors in the realm of echocardiology. Here is the bio for the Harvard lead: https://connects.catalyst.harvard.edu/Profiles/display/Person/21860

Re my governance issues, it does seem that at least until quite recently there has been a lack of experience with public and particularly listed companies within the Echo IQ team.

Ignorance is not an excuse so they do need to pull their socks up. I can point to a number of stuff-ups so it is not an isolated or ad hoc issue for them. For instance, this most recent announcement is the first time I have seen Echo IQ's product referred to as "EchoSolv" - all it needed was a one liner introducing the brand name but there is nothing I could see. Of more substance is that they stuffed up the appointment of the auditor at the AGM. Shareholders should not be expected to ratify such an important role - the very fact that it needs to be by way of a resolution at the AGM marks it's importance. Hopefully the recent appointment of an experienced practitioner as joint company secretary will help get everyone involved up to speed.